68 Recruiting Breast Neoplasms Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Top Recruiting Breast Neoplasms Studies
Optimizing Functional Recovery After Breast Cancer Treatment
📍 MGH Institute of Health Professions — Boston, Massachusetts
View Study & Checklist ➔Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
📍 University of Alabama at Birmingham-Medicine ( Site 0065) — Birmingham, Alabama
View Study & Checklist ➔Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
📍 Rhode Island and the Miriam Hospitals (Brown University Health) — Providence, Rhode Island
View Study & Checklist ➔A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
📍 Banner MD Anderson Cancer Center ( Site 0066) — Gilbert, Arizona
View Study & Checklist ➔(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
📍 Mayo Clinic Arizona — Phoenix, Arizona
View Study & Checklist ➔Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
📍 10 sites incl TX, WA, VA, and NV — Dallas, Texas
View Study & Checklist ➔Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique
📍 CHU Martinique — Fort-de-France,
View Study & Checklist ➔Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
📍 Research Site — Springdale, Arkansas
View Study & Checklist ➔Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
📍 Mayo Clinic Arizona — Phoenix, Arizona
View Study & Checklist ➔A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
📍 Southern Cancer Center (SCC) ( Site 8000) — Daphne, Alabama
View Study & Checklist ➔ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
📍 Highlands Oncology Group — Springdale, Arkansas
View Study & Checklist ➔Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
📍 Providence Medical Foundation — Fullerton, California
View Study & Checklist ➔I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
📍 Stanford University — Stanford, California
View Study & Checklist ➔A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
📍 Highlands Oncology Group - Duplicate 2 — Rogers, Arkansas
View Study & Checklist ➔Hypofractionated LocoRegional Radiotherapy in Breast Cancer
📍 Tom Baker Cancer Centre — Calgary, Alberta
View Study & Checklist ➔A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
📍 Alaska Oncology and Hematology — Anchorage, Alaska
View Study & Checklist ➔Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
📍 UCLA Hematology/Oncology - Parkside ( Site 0021) — Santa Monica, California
View Study & Checklist ➔Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
📍 Banner-University Medical Center Tucson Campus — Tucson, Arizona
View Study & Checklist ➔The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
📍 Pennington Biomedical Research Center — Baton Rouge, Louisiana
View Study & Checklist ➔A Study of LY4257496 in Participants With Cancer (OMNIRAY)
📍 City of Hope — Duarte, California
View Study & Checklist ➔Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
📍 St. Bernards Medical Center — Jonesboro, Arkansas
View Study & Checklist ➔A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
📍 Ironwood Cancer & Research Centers ( Site 0066) — Chandler, Arizona
View Study & Checklist ➔Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
📍 Mount Sinai Beth Israel Comprehensive Cancer Center West — New York, New York
View Study & Checklist ➔PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
📍 University of Alabama — Birmingham, Alabama
View Study & Checklist ➔Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI
📍 Toronto General Hospital — Toronto, Ontario
View Study & Checklist ➔A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
View Study & Checklist ➔A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
📍 Local Institution - 0303 — Hot Springs, Arkansas
View Study & Checklist ➔A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
📍 USO - Southern Cancer Center — Daphne, Alabama
View Study & Checklist ➔Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
📍 University of Colorado Anschutz Medical Campus ( Site 0057) — Aurora, Colorado
View Study & Checklist ➔A Study of DM001 in Patients With Advanced Solid Tumors
📍 Sarah Cannon Research Institute (SCRI) — Nashville, Tennessee
View Study & Checklist ➔Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors
📍 Centre de recherche du CHU de Québec — Québec, Quebec
View Study & Checklist ➔